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Abstract | Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder caused by the deficient 
production, secretion or action of gonadotropin-releasing hormone (GnRH), which is the master hormone 
regulating the reproductive axis. CHH is clinically and genetically heterogeneous, with >25 different causal 
genes identified to date. Clinically, the disorder is characterized by an absence of puberty and infertility. 
The association of CHH with a defective sense of smell (anosmia or hyposmia), which is found in ~50% of 
patients with CHH is termed Kallmann syndrome and results from incomplete embryonic migration of GnRH-
synthesizing neurons. CHH can be challenging to diagnose, particularly when attempting to differentiate it 
from constitutional delay of puberty. A timely diagnosis and treatment to induce puberty can be beneficial for 
sexual, bone and metabolic health, and might help minimize some of the psychological effects of CHH. In most 
cases, fertility can be induced using specialized treatment regimens and several predictors of outcome have 
been identified. Patients typically require lifelong treatment, yet ~10–20% of patients exhibit a spontaneous 
recovery of reproductive function. This Consensus Statement summarizes approaches for the diagnosis and 
treatment of CHH and discusses important unanswered questions in the field.
Boehm, U. et al. Nat. Rev. Endocrinol. 11, 547–564 (2015); published online 21 July 2015; doi:10.1038/nrendo.2015.112
Introduction
Congenital hypogonadotropic hypogonadism (CHH) 
is caused by deficient production, secretion or action 
of gonadotropin-releasing hormone (GnRH), a key 
neuro peptide that orchestrates mammalian reproduc-
tion.1 CHH is characterized by incomplete or absent 
puberty and infertility in the setting of isolated hypo-
gonadotropic hypogonadism (that is, otherwise normal 
anterior pitui tary function). CHH can present solely as 
congenital GnRH deficiency or be associated with other 
develop mental anomalies such as cleft lip or palate, 
dental agenesis, ear anomalies, congenital hearing 
impairment, renal agenesis, bimanual synkinesis or skel-
etal anomalies. When associated with anosmia or hyp-
o s mia, CHH is termed Kallmann syndrome, which 
results from abnormal embryonic migration of GnRH 
neurons from their origin in the olfactory placode to 
the forebrain.2,3 CHH has a male predominance of 3–5 
to 1.4,5 Most patients with CHH are diagnosed late in 
adolescence or early in adulthood as CHH is challen ging 
to differentiate from other causes of delayed puberty. 
Effective therapies in both men and women are available 
for the development of secondary sexual characteristics 
(virilization and/or estrogenization) and induction 
of fertility.
A number of important developments in the field have 
emerged over the past decade. Reversal of CHH occurs in 
~10–20% of patients,6,7 which challenges the dogma that 
the condition is lifelong. These data have implications 
for the management of CHH and suggest a plasticity of 
the GnRH neuronal system. Furthermore, inhibin B, 
insulin-like 3 (INSL3), anti-Müllerian hormone (AMH) 
and kisspeptin have emerged as biomarkers for use in 
the diagnosis and treatment of CHH.8,9 In addition, hor-
monal therapies are being personalized to maximize fer-
tility outcomes.10 Over the past few years, the traditional 
Mendelian view of CHH as a monogenic disorder has 
been revised following the identification of oligogenic 
forms of CHH,11 which has altered the approach adopted 
for genetic testing and genetic counselling of patients 
with CHH. Finally, the availability of next-generation 
sequencing has started to unravel the complex molecular 
basis of CHH. This Consensus Statement focuses on the 
pathogenesis, diagnosis and treatment of CHH in light of 
recent discoveries and differs from existing guidelines for 
the treatment of hypogonadism12–14 as it focuses exclu-
sively on CHH. Definitions of several key terms used in 
this article are presented in the glossary (Box 1).
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Methods
This Consensus Statement is the work of the European 
consortium studying GnRH biology (COST Action 
BM1105, http://www.gnrhnetwork.eu/). The COST 
network includes clinician investigators, geneticists, bio-
informaticians, basic scientists and patient advocates from 
28 countries. Our recommendations are based on a review 
of the literature published in the English language between 
1990 and 2015 using the following search terms: “congeni-
tal hypogonadotropic hypogonadism”, “idiopathic GnRH 
deficiency”, “central hypogonadism” and “Kallmann 
syndrome”. The reference lists of identified papers were 
searched for additional relevant articles. A series of meet-
ings and focused discussions with expert clinicians (spe-
cialized in paediatric and adult CHH) were conducted, 
with a final vetting process involving experts partici-
pating in the network from the fields of  endo crinology, 
 andrology, genetics and reproductive medicine.
Biology of the GnRH neuronal system
GnRH neurons are unusual neuroendocrine cells as 
they originate outside the central nervous system in 
the olfactory placode and then migrate into the brain 
during embryonic development.2,3 This route provides a 
developmental link between the central control of repro-
duction and the sense of smell, which are both affected 
in Kallmann syndrome. Data from the past few years 
suggest that GnRH neurons originate from both the 
neural crest and ectodermal progenitors, and migrate 
in close association with growing axons of olfactory 
and/or terminal nerves.15,16 Once in the hypothalamus, 
GnRH neurons detach from their axonal guides, disperse 
further into the brain parenchyma and stop migrating. At 
birth, GnRH neurons have reached their final destination 
in the brain and many of them project into the median 
eminence, where they release the GnRH decapeptide 
from their axon terminals into the hypophyseal portal 
vasculature.1 GnRH acts via the GnRH receptor, which is 
expressed on gonadotropic cells in the anterior pituitary 
gland. This action regulates both synthesis and release 
of gonadotropins such as luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH), which control 
gonadal maturation and adult reproductive physiology 
via the hypothalamic–pituitary–gonadal (HPG) axis.
Several genes mutated in Kallmann syndrome affect 
the fate and migration of GnRH neurons. Genes encoding 
fibroblast growth factor 8 (FGF8) signalling pathway pro-
teins,17–22 chromodomain helicase DNA-binding protein 7 
(CHD7)23–27 and sex determining region Y-Box 10 
(SOX10)28,29 affect the neurogenic niche in the nasal area 
and craniofacial development. Conversely, Kallmann syn-
drome protein, which is now officially known as anosmin 1 
(encoded by KAL1; following nomenclature change, the 
gene is now denoted as ANOS1),2  prokineticin- 2 and pro-
kineticin receptor 2 (encoded by PROK2 and PROKR2, 
respectively),30–33 WD repeat domain 11 (encoded by 
WDR11),34,35 semaphorin 3A (encoded by SEMA3A)36–38 
and FEZ family zinc finger 1 (encoded by FEZF1)39 
 influence migration of GnRH neurons.
Postmigratory GnRH neurons are embedded in a com-
plex neuronal network of afferents that send information 
about permissive reproductive cues such as steroid and 
metabolic hormones to these cells. Individual components 
of the underlying neural circuits are beginning to emerge. 
Some key molecules have been discovered through the 
study of the genetics of CHH.1 Inactivating mutations 
in genes encoding kisspeptin-1 (KISS1)40 and its recep-
tor (KISS1R)41,42 halt pubertal development in humans. 
Extensive experimental studies in various species have 
demonstrated that kisspeptin-producing neurons are 
major afferents to GnRH neurons and are essential for dif-
ferent aspects of GnRH function, ranging from the tonic 
feedback control of GnRH and/or gonadotropin secre-
tion to generation of the pre-ovulatory surge responsible 
for ovulation.43 Interestingly, although kisspeptins do not 
seem to be mandatory for proper GnRH neuron migration, 
compelling experimental work has documented that pop-
ulations of kisspeptin neurons undergo a dynamic process 
of prenatal and postnatal maturation that enables them to 
establish connections with GnRH neurons early in devel-
opment44 (under the control of steroid hormones45–47). 
Similarly, identification of mutations in TAC3 (encoding 
tachykinin-3, which is cleaved to form  neurokinin- B) and 
TACR3 (encoding tachykinin receptor 3; also known as 
neuromedin-K receptor [NKR])48–50 in patients with CHH 
highlights the important role of members of the tachyki-
nin family in the control of GnRH neurons. Furthermore, 
Box 1 | Glossary
Anosmia
Complete lack of sense of smell
Cryptorchidism
Maldescended testes that are not in the scrotum (that is, 
in the inguinal canal or abdomen); can occur in unilateral 
or bilateral forms
GnRH
GnRH is produced by specialized hypothalamic neurons 
in a pulsatile manner that stimulates the release 
of gonadotropins (luteinizing hormone and follicle-
stimulating hormone) from the pituitary, which activate 
gonadal maturation and fertility
Oligogenicity
Mutations in two (or more) CHH genes in one patient
Reversal
Recovery of the hypothalamic–pituitary–gonadal axis 
(normal circulating levels of sex steroids and/or fertility) 
after treatment discontinuation
Secondary sexual characteristics
Physical characteristics that result from increased sex 
hormone production during puberty
Virilization (male)
Change in external genitalia with phallic development, 
appearance of pubic and/or axillary and/or facial hair, 
enlarged larynx and/or deepening of voice and increased 
lean body mass
Estrogenization (female)
Breast development with prominence of nipples, 
development of pubic and axillary hair, widening of hips 
and development of labia minora
Abbreviations: CHH, congenital hypogonadotropic hypogonadism; 
GnRH, gonadotropin-releasing hormone.
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these findings led to the identification of a subpopula-
tion of afferent neurons in the arcuate and/or infundibu-
lar hypothalamic region, which co-express kiss peptins 
and NKB.51 Interestingly, data from the past few years 
suggest that the actual number of kisspeptin and/or NKB 
neurons might change during development.52,53 Mutations 
in proteins that regulate ubiquitination such as OTU 
domain-containing protein 4 (encoded by OTUD4) and 
E3 ubiquitin-protein ligase RNF216 (also known as ring 
finger protein 216; encoded by RNF216),54 as well as in 
proteins involved in lipid metabolism such as neuropathy 
target esterase (also known as patatin-like phospholipase 
domain-containing protein 6; encoded by PNPLA6)55,56 
have been identified in patients with Gordon Holmes syn-
drome (with associated CHH and ataxia). Thus, mutations 
in these three genes give rise to a broad and progressive 
neurodegenerative syndrome that includes CHH. In 2014, 
haploinsufficiency of DMXL2, which encodes synaptic 
protein DmX-like protein 2, was shown to cause a complex 
new syndrome associating CHH with  polyendocrine 
 deficiencies and polyneuropathies.57
Peripheral signals that convey information about meta-
bolic status indirectly modulate GnRH neuro secretion. 
This modulation is well illustrated by the reproductive 
phenotype of absent pubertal development and hypo-
gonadotropic hypogonadism in patients with inacti-
vating mutations in the genes encoding leptin (LEP) or 
its receptor (LEPR).58 Exactly how the effects of leptin 
are transmitted to GnRH neurons is unknown, as this 
neuro nal population does not express the leptin recep-
tor.59 Experimental data suggest that kisspeptin neurons 
are sensitive to changes in leptin concentrations and 
metabolic conditions,43 yet they apparently do not express 
functional leptin receptor, which indicates the mode of 
action is indirect.60 Primary leptin targets for conduction 
of its reproductive effects probably include nitric oxide-
producing neurons in the pre-optic hypothalamus61 and 
neuronal circuits in the ventral premammillary nucleus,60 
which might transmit metabolic information to GnRH 
neurons through kiss peptin dependent and/or indepen-
dent pathways. Taken together, the identification of genes 
mutated in the different forms of CHH has facilitated an 
improved understanding of the neuroendocrine control 
of reproduction.
Puberty and reproduction
Puberty represents a period of transition from child-
hood into adulthood during which complete reproduc-
tive capacity is attained. Puberty is regulated by the HPG 
axis. The axis is active in utero and shortly after birth62,63 
(a phenomenon referred to as mini-puberty), is subse-
quently silenced and remains quiescent for years until 
reawakening at the onset of puberty. Multiple central 
and peripheral inputs are integrated into pubertal 
reacti vation of the GnRH pulse generator.64 At the onset 
of puberty, GnRH-induced pulses of LH are initially 
nocturnal and, gradually, the pulsatility extends to the 
daytime as puberty progresses.65–67
In boys, FSH stimulates proliferation of immature 
Sertoli cells and spermatogonia, whereas LH stimulates 
Leydig cells to produce testosterone. The concerted stimu-
lation of Sertoli cells by FSH and intragonadal testos terone 
levels 50–100-fold higher than in the systemic circulation 
leads to the initiation of spermatogenesis. In girls, the 
early stages of follicular growth are primarily driven by 
intra-ovarian factors. FSH and LH are needed for follicular 
maturation, which leads to ovulation. More specifically, 
LH stimulates theca cells to produce androgens and FSH 
stimulates recruitment of secondary ovarian follicles and 
the secretion of estradiol from granulosa cells. Inhibin B 
and AMH are produced by prepubertal Sertoli cells and 
granulosa cells.68 Circulating levels of inhibin B increase 
during puberty in girls and boys.69,70 AMH concentrations 
show only minor fluctuations during female puberty.71 In 
boys, AMH concentrations fall as Sertoli cells differenti-
ate and testos terone production increases.72 In male indi-
viduals, INSL3 is secreted by Leydig cells during fetal and 
immediate postnatal life.8,73 Testicular INSL3 secretion 
declines during childhood before increasing at the time 
of puberty and peaking during adulthood.74
Early signs of puberty manifest around the age of 
10 years in girls (breast development) and 11.5 years in 
boys (testicular enlargement and spermarche—appearance 
of spermatozoa in first morning void).75–77 Considerable 
interindividual variation in the timing of pubertal onset 
exists, ranging from 8 years to 13 years in girls and 9 years 
to 14 years in boys.78,79 Subsequent hallmarks of puberty in 
boys include deepening of the voice and a growth spurt. In 
girls, menarche occurs at ~12.5 years of age.78
Clinical presentation of CHH
Neonatal and childhood
Lack of neonatal activation of the HPG axis can provide 
early diagnostic cues for identifying CHH at birth or 
during mini-puberty.80–83 In male infants, crypt orchidism 
(that is, maldescended testes) and micropenis can be 
signs of GnRH deficiency (Figure 1), yet these fea-
tures are by no means invariable.84–86 As penile growth 
occurs during infancy and childhood, micropenis can 
be assessed using available cross-sectional normative 
data.87,88 These two clinical clues warrant hormonal 
monitoring during mini-puberty. However, more severe 
genital anomalies, such as hypospadias, point away from 
a diagnosis of CHH and, instead, indicate a defect of 
human chorionic gonadotropin (hCG)-driven androgen 
secretion and/or action in early fetal life, before the initi-
ation of endogenous GnRH activity. No specific clinical 
signs of CHH present in female neonates. Regardless 
of sex, when infants are born to parents with CHH, 
we recommend monitoring reproductive hormones 
during mini-puberty and performing genetic testing if 
 mutations have been identified in the parents.
Adolescent
The timing and onset of puberty varies widely in the 
general population.89 Delayed puberty is classically 
defined as absence of testicular enlargement (volume 
<4 ml) in boys by the age of 14 years and absent breast 
development in girls by the age of 13 years.90 In addition, 
use of the stage-line diagram enables the identification of 
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patients with delayed puberty, which is based not only on 
pubertal onset but also on the tempo of pubertal devel-
opment.91 In most of these individuals, puberty is initi-
ated and eventually completed (that is, constitutional 
delay of growth and puberty [CDGP]). By contrast, 
adolescents with CHH lack pubertal activation of the 
HPG axis, which leads to absent puberty and infertil-
ity (Figure 1). In the majority of patients, puberty never 
occurs (absent puberty); less commonly, puberty is initi-
ated then arrested (partial puberty).92–94 Adolescents 
with CHH exhibit steady linear growth and thus lack the 
so-called growth spurt.91,95,96 Given the delayed epiphy-
seal closure, these individuals often have eunuchoidal 
proportions. The most common complaints in male 
adolescents with CHH include absent and/or minimal 
viriliza tion, low libido and lack of sexual function. 
Among female adolescents, lack of breast develop ment 
and/or primary amenor rhoea by the age of 15 years 
are frequent complaints. In addition, patients with 
CHH often have low self-esteem, distorted body image, 
impaired psychosexual development and, in some 
cases, problems with sexual identity.97,98 Furthermore, 
small studies have shown increased anxiety and depres-
sion among adolescents with CHH and, as such, these 
 symptoms merit attention.99,100
The clinical heterogeneity of CHH makes differen-
tiation from CDGP, which is usually associated with 
short stature, poor growth velocity and delayed skeletal 
maturation, difficult.90,95 The presence of micropenis 
and/or cryptorchidism argues firmly in favour of CHH, 
as these features are rarely seen in CDPG. Associated 
congenital phenotypes are also very useful as they indi-
cate a syndromic form of CHH. The classic, and by far 
most frequent, form being Kallmann syndrome, which 
includes anosmia. Other phenotypes like cleft palate or 
sensorineural deafness also suggest a syndromic form of 
CHH,94 most often associated with Kallmann syndrome, 
but not exclusively so.18 The clinical sign that points 
away from CDGP is a poor sense of smell, which sug-
gests Kallmann syndrome.101–103 Other ‘red flags’ include 
congenital hearing impairment with or without pigmen-
tation defects, bimanual synkinesia (mirror movements), 
dental agenesis, cleft lip and/or palate and crypt orchid-
ism with or without micropenis.17,28,104–108 Family history 
indicative of autosomal inheritance cannot be used as a 
diagnostic tool, as this feature can be observed in both 
CHH and CDGP.109
Adulthood
CHH might be diagnosed after adolescence, when 
patients present for evaluation of infertility or even 
for osteo poro tic fractures. This delay in diagnosis 
might be related to missed opportunities to diagnose 
CHH in adolescence or a reluctance of patients to seek 
medical evaluation.
Genetics of CHH
CHH is genetically heterogeneous, with both sporadic 
and familial cases. Several modes of inheritance have 
been identified, including X chromosome-linked reces-
sive, autosomal recessive and dominant.1 By examining 
milder phenotypes (such as delayed puberty or isolated 
anosmia), the frequency of familial cases increases.110,111 
Understanding of the molecular genetics of CHH and 
Kallmann syndrome has advanced tremendously in 
the past 20 years, since the first gene associated with 
Kallmann syndrome (KAL1 [ANOS1]) was identified by 
a positional cloning strategy in 1991 (Table 1).112–115 KAL1 
(ANOS1) encodes anosmin-1, a transiently expressed, 
locally restricted glycoprotein of embryonic extracellu-
lar matrices116 that is involved in fibroblast growth factor 
(FGF) signalling.117,118 To date, >25 different genes have 
been implicated in Kallmann syndrome and/or CHH, 
which accounts for ~50% of cases.21 Causative genes 
for Kallmann syndrome include: KAL1 (ANOS1) in 
the X-linked form; FGFR1 (encoding fibroblast growth 
factor receptor 1),17,18 FGF8,19,119 CHD7,23–27 HS6ST1 
(encoding heparan-sulphate 6-O-sulphotransferase 1),20 
SOX10,28,29 SEMA3A (encoding semaphorin-3A),36–38 
WDR11 (encoding WD repeat-containing protein 11)34,35 
and IL17RD (encoding interleukin-17 receptor D)21 
in the autosomal dominant form; and PROKR2 and/or 
PROK2,30–33 and FEZF139 in the autosomal recessive form, 
even though it should be noted that most patients carry-
ing mutations in PROKR2 or PROK2 carry these muta-
tions in the heterozygous state.120,121 Genes involved 
in CHH that are associated with a normal sense of 
smell include GNRHR (encoding gonadotropin-
releasing hormone receptor),122,123 GNRH1 (encoding 
gonadotropin- releasing hormone 1),124,125 KISS1R,41,42 
KISS1,40,126 TACR3 and TAC3.48–50 Other genes such as 
FGFR1 or PROKR2 can be mutated in patients with either 
Kallmann syndrome or CHH (Table 1). Remarkably, 
mutations in each Kallmann syndrome or CHH gene 
identified so far account for <10% of cases.11,21,127
CHH has classically been categorized as a monogenic 
disorder, which means that one defective gene is suffi-
cient to account for the disease phenotype. As such, CHH 
and Kallmann syndrome caused by mutations in GNRHR 
(a recessive gene) and KAL1 (ANOS1; an X-linked gene), 
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■ Cryptorchidism (M) 
■ Micropenis (M) 
■ Prepubertal testes 
 (M) 
■ Undervirilization (M)   
■ Absent breast 
 development (F) 
■ Primary 
 amenorrhoea (F)  
■ Infertility (M and F) 
H
PG
-a
xi
s 
ac
tiv
ity
Figure 1 | Activity of the HPG axis across the lifespan. Normal GnRH and LH 
secretion from fetal life to adulthood (blue line) compared with non-reversible 
CHH (red line). Reproductive phenotypes observed in CHH are listed under the 
respective stage of development. Abbreviations: CHH, congenital hypogonadotropic 
hypogonadism; F, female; GnRH, gonadotropin-releasing hormone; HPG, 
hypothalamic–pituitary–gonadal; LH, luteinizing hormone; M, male.
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respectively, are highly penetrant,127 yet such a pattern 
is not observed for all genes involved in CHH and/or 
Kallmann syndrome. For instance, the p.Arg622X FGFR1 
mutation has been reported in unrelated Kallmann syn-
drome and CHH probands (Figure 2). Examination of 
pedigrees reveals low penetrance for most CHH genes 
and variable expressivity among affected individuals 
carry ing the same gene defect. Such an observation led 
to the hypothesis that multiple gene defects could syner-
gize to produce a more severe CHH phenotype (that is, 
oligo genicity).30,128 Studies in large CHH cohorts indi-
cate that at least 20% of cases are oligogenic11,21 (Table 1). 
This genetic model might be useful to predict genotype– 
phenotype correlations.5 Interestingly, genome-wide 
associ ation studies have identified >100 loci affecting 
the age of menarche,129 which confirms a genetic con-
tribution to pubertal timing. Surprisingly, little overlap 
exists between the genes implicated in age at menarche 
and CHH.129
Diagnosis of CHH
Central to the evaluation process for diagnosing CHH is 
the exclusion of differential diagnoses such as pituitary 
tumour or functional causes (Box 2).
Table 1 | Genes implicated in CHH
Gene OMIM CTO CHH phenotypes Overlapping syndromes
KS CHH CHH 
reversal
CPHD CPHD  
+ SOD
WS CHARGE HS SHFM D‑WS MGS PEPNS GHS
KAL1 
(ANOS1)
300836 × × × × × × × × × × ×
SEMA3A 614897 × × × × × × × × × × × ×
SOX10 602229 × × × × × × × × × × × ×
OL14RD 606807 × × × × × × × × × × × ×
HESX1 182230 × × × × × × × × × × ×
FEZF1 613301 × × × × × × × × × × × × ×
FGFR1 147950 × × × × × ×
FGF8 612702 × × × × × × × × × ×
CHD7 612370 × × × × × × × × × ×
FGF17 603725 × × × × × × × × × ×
HS6ST1 614880 × × × × × × × × × ×
PROK2 610628 × × × × × × × × × × ×
PROKR2 147950 × × × × × × × ×
SEMA7A 607961 × × × × × × × × × × ×
WDR11 614858 × × × × × × × × × ×
NSMF 614838 × × × × × × × × × ×
AXL 109135 × × × × × × × × × × × ×
GNRH1 614841 × × × × × × × × × × × × ×
GNRHR 146110 × × × × × × × × × × ×
KISS1 614842 × × × × × × × × × × × × ×
KISS1R 614837 × × × × × × × × × × × ×
TAC3 614839 × × × × × × × × × × ×
TACR3 614840 × × × × × × × × × × ×
LEP 614962 × × × × × × × × × × × × ×
LEPR 614963 × × × × × × × × × × × × ×
PCSK1 162150 × × × × × × × × × × × × ×
DMXL2 616113 × × × × × × × × × × × ×
RNF216 609948 × × × × × × × × × × × ×
OTUD4 611744 × × × × × × × × × × × ×
PNPLA6 603197 × × × × × × × × × × × ×
NR0B1 300200 × × × × × × × × × × × × ×
Abbreviations: CHH, congenital hypogonadotropic hypogonadism; CHARGE, coloboma, heart defects, atresia of choanae, retardation of growth and/or development, genital and/or urinary 
defects, ear anomalies or deafness; CPHD, combined pituitary hormone deficiency; CTO, contributes to oligogenicity; D-WS, Dandy-Walker syndrome; GHS, Gordon Holmes syndrome; HS, 
Hartsfield syndrome; KS, Kallmann syndrome; MGS, Morning Glory syndrome; OMIN, online Mendelian inheritance in man; PEPNS, polyendocrine deficiencies and polyneuropathies; SHFM, 
split-hand/foot malformation; SOD, septo-optic dysplasia; WS, Waardenburg syndrome.
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Clinical, biochemical & imaging investigations
The mini-puberty provides a brief opportunity to iden-
tify CHH. For male infants, cryptorchidism with or 
without micropenis can be suggestive of CHH (Figure 1). 
In such cases, hormone profiling at 4–8 weeks of life can 
be used to make a diagnosis83,85 based on comparisons 
with established reference ranges for gonadotropins, sex 
steroids and inhibin B levels.62,63,70,130 Female neonates 
born to parents with CHH should undergo biochemical 
evaluation; serum levels of FSH during the mini-puberty 
seem to be the most sensitive indicator of CHH in this 
setting.131 During childhood, diagnosis of CHH is very 
challenging as this interval is a physiologically hypo-
gonadal period of development. Undetectable levels of 
FSH (but not of LH) or absence of response to a GnRH 
test in childhood might indicate CHH.
CHH diagnosis is typically made during adolescence 
or early adulthood (Table 2). Approximately half of 
patients with CHH have Kallmann syndrome.101 Self-
report of anosmia is reliable, yet claims of having a 
‘good’ sense of smell do not always align with formal 
smell testing. Most patients with Kallmann syndrome 
display olfactory bulb hypoplasia and/or aplasia on 
brain MRI; however, this finding is not fully concordant 
with sense of smell.102 An assessment of family history is 
important to identify familial cases. A family history of 
CDGP does not exclude CHH as pedigrees of patients 
with CHH seem to be enriched in delayed puberty, 
subfertility and anosmia or hyposmia.132 A detailed 
physical examination is needed, with particular atten-
tion paid to genitalia (that is, measurement of testicular 
volume using a Prader orchidometer) and virilization 
and/or estrogenization (that is, Tanner staging for 
breast development and pubic hair133,134). Eunuchoidal 
proportions are often present.135 A stage-line diagram 
is useful for providing developmental stages ±SD or as 
percentiles, as well as the tempo of pubertal develop-
ment ±SD per year.91 Additionally, signs of associated 
developmental anomalies such as cryptorchidism with 
or without micropenis, midline defects or signs sugges-
tive of combined pituitary hormone deficiency should 
be evaluated (Box 2).
Biochemical evaluation includes a variety of tests to 
exclude other causes of CHH such as pituitary tumour or 
functional causes (Table 3). Isolated hypogonadotropic 
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Figure 2 | FGFR1 mutation p.Arg622X in an autosomal dominant form of CHH with incomplete penetrance and variable 
expressivity. In family 1, the CHH phenotype is fully penetrant.147 In the three other pedigrees, family members carrying 
the same FGFR1 mutation have variable reproductive and olfactory phenotypes and family 2 includes an asymptomatic 
carrier.17,148 + denotes wild-type allele. Abbreviation: CHH, congenital hypogonadotropic hypogonadism.
Box 2 | Forms of CHH and differential diagnosis
Forms of CHH
GnRH deficiency and defective sense of smell
 ■ Kallmann syndrome
Isolated GnRH deficiency (normal sense of smell)
 ■ Normosmic CHH
Complex syndromes including CHH or KS
 ■ Combined pituitary hormone deficiency
 ■ Septo-optic dysplasia
 ■ CHARGE syndrome
 ■ Adrenal hypoplasia congenita with HH
 ■ Waardenburg syndrome
 ■ Bardet–Biedl syndrome
 ■ Gordon Holmes syndrome
 ■ Others
Differential diagnosis
Functional causes
 ■ Malnutrition and/or malabsorption
 ■ Any chronic disease (for example, IBS or asthma)
 ■ Coeliac disease
 ■ Eating disorders
 ■ Excessive exercise
Systemic causes
 ■ Haemochromatosis
 ■ Sarcoidis
 ■ Histiocytosis
 ■ Thalassaemia
Acquired causes
 ■ Pituitary adenomas and/or brain tumours
 ■ Rathke’s cleft cyst
 ■ Pituitary apoplexy
 ■ Radiation (brain or pituitary)
 ■ Medication induced (such as, by steroids, opiates  
or chemotherapy)
Abbreviations: CHARGE, coloboma, heart defects, atresia of 
choanae, retardation of growth and/or development, genital  
and/or urinary defects, ear anomalies or deafness; CHH, 
congenital hypogonadotropic hypogonadism; GnRH, gonadotropin-
releasing hormone; HH, hypogonadotropic hypogonadism; IBS, 
irritable bowel syndrome; KS, Kallmann syndrome.
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hypogonadism is characterized by low serum levels of 
testosterone in male individuals (usually <2 nmol/l) in 
the setting of low or normal serum levels of gonado-
tropins (LH and FSH) with otherwise normal pituitary 
function (Figure 3). In female individuals, serum levels 
of estradiol are often low, sometimes undetectable in the 
setting of low-normal gonadotropin levels. Serum levels 
of estradiol seem to correlate with breast development, as 
most women with absent breast development have very 
low or undetectable levels, whereas women with breast 
development exceeding Tanner stage B2 usually have 
measurable serum levels of estradiol.
In early adolescence (13–16 years), a diagnosis of CHH 
is challenging to make as isolated hypogonadotropic 
hypogonadism is common to both CHH and CDGP. In 
CHH, the GnRH stimulation test has a poor diagnostic 
value. In the absence of a gonadotropin response, this test 
can help to confirm severe GnRH deficiency, yet clini-
cal signs are often already evident (that is, prepubertal 
testes or absence of breast development). By contrast, the 
GnRH stimulation test rarely enables differentiation of 
CDGP from partial forms of CHH—the most challen-
ging differential diagnosis. A number of other tests have 
been proposed to differentiate between these two enti-
ties, including a combination of GnRH and hCG stimu-
lation tests, as well as measurement of serum levels of 
inhibin B, AMH or INSL3.74,136–142 However to date, no 
gold-standard diagnostic test exists to fully differentiate 
CHH from CDGP.143
Inhibin B is a marker of Sertoli cell number and cor-
relates with testicular volume.92 In men with CHH and 
severe GnRH deficiency, serum levels of inhibin B are 
typically very low (<30 pg/ml; Figure 3). However, for 
partial forms of CHH, inhibin B levels overlap with those 
in patients with CDGP and in healthy controls.138,139 
INSL3 is a good marker of Leydig cell function144 and, as 
such, levels of INSL3 are typically low in male individuals 
with CHH (at diagnosis or on testosterone therapy) and 
increase with LH and/or hCG stimulation.74 However, 
further studies are needed to identify the potential clini-
cal utility of INSL3 measurements, such as differentiating 
CHH from CDGP or as a predictor of reversible CHH. 
Kisspeptin is a potent stimulator of GnRH-induced LH 
secretion.9 Exogenous kisspeptin administration failed 
to induce a response in patients with CHH regardless 
of genotype. However, a male individual with revers-
ible CHH exhibited a robust response to exogenous 
kisspeptin145 and continuous kisspeptin infusion was 
demonstrated to overcome genetic defects in the kiss-
peptin signalling pathway.146 In terms of clinical applica-
tion, kiss peptin has been used with therapeutic effect in 
women with hypothalamic amenorrhoea,147 as well as for 
egg maturation during assisted fertility.148 Thus, although 
still investigational, kisspeptin seems to be emerging as 
useful in several therapeutic areas.
CHH work-up also includes cranial MRI to assess 
for tumours and/or space occupying lesions and to 
visualize inner ear and olfactory structures, bone age 
in adolescents to compare with chronological age and 
to assess epiphyseal closure, abdominal and/or pelvic 
ultra sonography to assess unilateral renal agenesis and 
to visualize the ovaries and/or uterus or testis, and bone 
densitometry (dual-energy X-ray absorptiometry) to 
assess bone density.
Genetic testing
Genetic testing is useful for diagnosis, prognosis149 and 
genetic counselling in CHH.127 The first step in priori-
tizing genes for genetic testing is to establish the inheri-
tance pattern. Briefly, X-linked inheritance is observed in 
pedigrees when male-to-male transmission of the disease 
phenotype does not occur but the disease is observed in 
male members of the maternal line. This feature is typical 
for KAL1 (ANOS1) mutations underlying Kallmann syn-
drome.150 Autosomal dominant inheritance is observed in 
a family with vertical transmission of the disease pheno-
type across one or more generations. In this setting, male 
and female individuals are equally affected and male-to-
male transmission can be observed. Importantly, incom-
plete penetrance and variable expressivity of the disease 
among people with identical mutations can be observed 
for most CHH genes (Figure 2).17,151,152 In autosomal 
recessive inheritance, vertical transmission of the disease 
phenotype does not occur and ~25% of offspring are 
affected. Examples of autosomal recessive forms include 
those involving mutations in GNRHR, KISS1R, TACR3, 
PROKR2 or FEZF1 (Table 1).
Genetic testing can also be guided by the presence of 
additional phenotypic features. Cleft lip and/or palate 
Table 2 | Clinical evaluation of CHH
Assessment Signs Focus
Growth Evaluation of growth (growth chart) Linear growth, acceleration  
and/or deceleration in growth
Eunuchoidal proportions Closure of epiphysis
Sexual Cryptorchidism and micropenis Severe CHH in male individuals
Sexual development (Tanner staging 
of pubic hair, penis and gonads  
in male individuals and breasts in 
female individuals)
Puberty (Tanner stage 2 
genitalia in male individuals 
indicates the onset of puberty)
Male individuals: testicular 
volume (Prader orchidometer) 
and penile length
Male individuals: at age 
14 years, testicular volume 
<4 ml indicates absent puberty
Assess micropenis (versus 
cross-sectional normative data)
Female individuals: breast 
development and age at menarche
Female individuals: at age 
13 years, Tanner stage 1 
breasts indicate absent puberty
Primary amenorrhoea by age 
15 years
Other Olfaction (using odorant panel  
and/or olfactometry)
Hyposmia and/or anosmia
Snellen eye chart, ocular fundoscopy Optic nerve hypoplasia
External ear shape and audition Hearing impairment
Number of teeth Cleft lip and/or palate, missing 
tooth or teeth
Pigmentation of skin and hair Achromic patches
Rapid sequential finger–thumb 
opposition
Bimanual synkinesis
Neurodevelopmental delay
Abbreviation: CHH, congenital hypogonadotropic hypogonadism.
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and skeletal anomalies indicate mutations in genes 
encoding components of the FGF8 signalling pathway 
(for example, FGFR1, FGF8 and HS60ST1).17,20,21,104,153 
Signs associated with CHARGE syndrome (CHARGE: 
coloboma, heart defects, atresia of choanae, retardation 
of growth and/or development, genital and/or urinary 
defects, and ear anomalies and/or deafness) favour 
screening for mutations in CHD7.24–26,104 Likewise, the 
association of CHH with congenital hearing impairment 
should direct screening towards CHD7, SOX10 and/or 
IL17RD.21,28,104 Bimanual synkinesia or renal agenesis 
are important clinical cues suggestive of KAL1 (ANOS1) 
mutations.101,104,114,154,155 Early onset of morbid obesity 
associated with CHH suggests mutations in LEP, LEPR 
or PCSK1.58,156 Indeed, combining CHH with specific 
associated phenotypes can increase the probability of 
finding causal mutations by targeted gene sequencing 
(Figure 4).21,28,104,157 CHH accompanied by other syn-
dromic features such as congenital ichthyosis158 or sphero-
cytosis159 is suggestive of a contiguous gene syndrome for 
which a karyotype or comparative genomic hybridization 
array analysis might be useful for identifying underlying 
chromosomal abnormalities.159–161
Genetic counselling
A legitimate question often raised by patients with CHH 
relates to the risk of passing on the disease to their off-
spring.26,127,162 When autosomal dominant transmission 
is suspected, the patient and partner should receive 
genetic counselling before fertility-inducing treatment. 
This counselling should include clear explanation of the 
50% theoretical risk of transmitting the disease. In such 
cases, hormonal profiling during mini-puberty should 
be conducted. In proven autosomal recessive forms, 
which affect both male and female individuals, the risk 
of disease transmission to offspring is very low in the 
absence of consanguinity (that is, inter-related parents). 
This reduced risk is due to the very low frequency of 
heterozygous healthy carriers in the general population, 
which should be reassuring for intended parents. Male 
individuals with X-linked Kallmann syndrome should 
be informed of the automatic transmission of the muta-
tion to their unborn daughters (obligate carriers) and the 
necessity for genetic counselling of these girls after the 
age of puberty. When patients carry several mutations 
in different CHH or Kallmann syndrome genes (that 
is, oligogenicity), genetic counselling is difficult and 
the transmission risk is variable.127 Finally, the advent 
of next-generation sequencing will probably improve 
the molecular genetic diagnosis of CHH.163 More spe-
cifically, this technology will help identify cases of oligo-
genicity and might promote personalized approaches to 
genetic counselling.
Treatment of CHH
No treatments exist for many of the CHH-associated 
phenotypes such as anosmia, bimanual synkinesia 
or renal agenesis. Others phenotypes such as cleft lip 
and/or palate, hearing loss or various skeletal defects 
require surgical and/or specialist intervention early in 
life. The approach to CHH treatment is largely deter-
mined by goals such as developing only virilization or 
 estrogenization, or inducing fertility as well.
During infancy and childhood
In affected boys, the focus of most treatment is on 
appropriate testicular descent and penile growth. 
Cryptorchidism (particularly bilateral) can have far 
reaching negative effects on future fertility potential.164,165 
As such, current recommendations advocate surgical 
correction at 6–12 months.166–168 Micropenis should be 
treated early using short-term, low-dose testos terone 
(dihydrotestosterone or testosterone esters) to induce 
penile growth (Table 4).86,169 Importantly, as the duration 
of treatment is brief, no major concerns regarding viril-
ization or the development of secondary sexual charac-
teristics exist; however, erections might be observed. 
Gonadotropins (LH and FSH) have been used to treat 
patients with micropenis and evidence of absent mini-
puberty.170,171 Such an approach might be beneficial for 
the additional stimulatory effect on gonadal develop-
ment. Indeed, treatment with FSH stimulates prolifera-
tion of immature Sertoli cells and spermatogonia in men 
with CHH before pubertal induction.10 Furthermore, 
Table 3 | Biochemical, radiological and genetic evaluation of CHH
Assessment Marker Focus
Biochemical 0800–1000 h hormonal 
measurements (LH, FSH, 
testosterone or estradiol, 
prolactin, free T4, TSH, cortisol, 
IGF-1 and IGFBP3)
Assess for combined pituitary hormone 
deficiency
Demonstrate isolated hypogonadtropic 
hypogonadism
Specialized endocrine tests 
(serum inhibin B, AMH,  
INSL3, GnRH and/or hCG 
stimulation test)
Evaluate the degree of GnRH deficiency 
and function of the gonads
Spermiogram Assess fertility
Liver and/or renal function and 
inflammatory markers (LFTs, 
BUN, lytes, CBC, Ca, CRP, ESR 
and faecal calprotectin)
Assess systemic and/or inflammatory 
disease
Screen for coeliac disease Assess malabsorption
Iron overload screen (ferritin, 
TIBC% saturation)
Assess juvenile haemochromatosis
Radiologic Wrist radiography (bone age) Delayed bone age (chronological age 
greater than bone age)
Brain MRI Exclude hypothalamo–pituitary lesion
Assess olfactory bulbs and sulci
Visualize optic nerve
Assess inner ear (semicircular canals)
Renal ultrasonography Rule out unilateral renal agenesis
Bone density (DXA) Assess osteopenia and/or 
osteoporosis
Genetic Comparative genomic 
hybridization array or karyotype
Large, rare deletions and/or insertions 
to identify contiguous gene syndromes
Gene screening (Sanger or 
next-generation sequencing)
Mutations in CHH and/or KS genes
Abbreviations: AMH, anti-Müllerian hormone; BUN, blood urea nitrogen; CBC, complete blood count; CHH, 
congenital hypogonadotropic hypogonadism; CRP, C-reactive protein; DXA, dual-energy X-ray absorptiometry; 
ESR, erythrocyte sedimentation rate; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing 
hormone; hCG, human chorionic gonadotropin; IGF-1, insulin growth factor 1; IGFBP3, insulin-like growth 
factor-binding protein 3; INSL3, insulin-like 3; KS, Kallmann syndrome; LFTs, liver function tests; LH, 
luteinizing hormone; TIBC, total iron-binding capacity.
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neonatal gonadotropin therapy can increase intra-
testicular testosterone concentrations without fear of 
inducing spermatogenesis or negatively affecting the 
ultimate number of Sertoli cells (an important deter-
minant of fertility), as Sertoli cells do not express the 
androgen receptor during the first 5 years of life.172,173 
Although initial studies involving neonatal administra-
tion of gonadotropin have been promising, these studies 
are limited, both in number of studies and number of 
participants, and further investigations are needed to 
examine the effectiveness of gonadotropin and its effect 
on long-term outcomes such as fertility (Box 3).
During adolescence and adulthood
The aim of treatment is to induce virilization or estro-
genization and normal sexual function, to stimulate 
statural growth, to promote bone health and to address 
concerns about future fertility as well as psychological 
and emotional wellbeing.174,175 Sex steroid therapy (that 
is, testosterone in male individuals and estradiol before 
estradiol + progesterone in female individuals) induces 
the characteristic changes of puberty, which includes 
psychosocial development (Table 4).
Induction of male sexual characteristics
Virilization is typically the primary objective of treat-
ing CHH174 in order to diminish the psychological suf-
fering caused by sexual infantilism.97,98,176 Accordingly, 
prompt initiation of therapy after diagnosis is important 
and usually involves an injectable testosterone ester 
(aromatizable androgen such as enanthate, cypionate or 
undecanoate) or transdermal testosterone application 
with the precise protocol depending on the age at diag-
nosis and local practice.94,177,178 Paediatric endocrinolo-
gists treating young patients (that is, from 12 years of 
age) usually begin treatment with low-dose testos-
terone (for example, 50 mg of testosterone enanthate 
monthly, 10 mg transdermal testosterone every second 
day, or 40 mg oral testosterone undecanoate daily) and 
gradually increase to full adult dosing over the course 
of 18–24 months, depending on age at the start of treat-
ment. Such regimens help mimic natural puberty and 
maximize statural growth while affording time for 
psycho sexual development and minimizing the risk of 
precocious sexual activity.95,174
Adult endocrinologists often see patients with CHH 
in late adolescence or early adulthood when the main 
complaint is the lack of pubertal development.94 In such 
cases, the therapeutic approach is often more incisive 
than for younger patients, involving higher initial tes-
tosterone doses (200 mg testosterone enanthate monthly, 
then every 2–3 weeks) than those used by paediat-
ric endocrinologists to induce more rapid virilization 
(Box 4). The frequency of injections should be guided 
by trough serum testosterone measurement targeting 
the lower end of the normal range to avoid periods of 
hypogonadism between injections. Of note, testoster-
one treatment will not induce gonadal maturation or 
fertility in these patients.94,177 Importantly, increased 
testicular volume following testosterone treatment is an 
indicator of reversal6,7,179–185 and requires re-assessment 
of the HPG axis in the absence of testosterone replace-
ment therapy. An estimated 10–20% of patients with 
CHH undergo spontaneous recovery of reproductive 
function,6,7 and this includes patients with mutations in 
known CHH genes (Table 1). Moreover, reversal is not 
always lasting7,184 and, as yet, no predictors to identify 
those who will reverse or relapse exist (Box 3). Ongoing 
monitoring is thus justified.
Virilization in adolescents or young adults can also 
be achieved with pulsatile GnRH186–188 or gonadotropin 
therapy (hCG alone or combined with FSH).189,190 These 
fertility-inducing treatments stimulate endogenous 
testosterone (and estradiol) production by testicular 
Leydig cells and are associated with good physical and 
psychological outcomes.191 In clinical practice, testos-
terone enanthate is the most frequently used treatment 
for young adults, yet clinicians should avoid adher-
ence to an overly dogmatic approach. Few published 
studies have examined the effects of treatment to induce 
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Figure 3 | Hormonal profile of patients with CHH and/or KS compared with healthy 
controls. a | Serum testosterone levels. b | Serum gonadotropin (LH and FSH) 
levels. c | Serum inhibin B levels. d | Serum INSL3 levels. Healthy male individuals 
(controls; aged 17—27 years) versus untreated patients with CHH and/or KS 
(aged 17–29 years). Abbreviations: CHH, congenital hypogonadotropic 
hypogonadism; FSH, follicle-stimulating hormone; INSL3, insulin-like 3; LH, 
luteinizing hormone; KS, Kallmann syndrome. Adapted with permission from The 
Endocrine Society © Trabado, S. et al. J. Clin. Endocrinol. Metab. 99, E268–E275 
(2014) and Young, J. J. Clin. Endocrinol. Metab. 97, 707–718 (2012).
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virilization, as well as fertility treatment, on quality of 
life and sexuality in men with CHH,97,98,192 particularly 
in those with severe CHH (micropenis and cryptorchid-
ism). Regardless of the therapy considered, patients 
and their entourage (that is, spouse, partner or family) 
should be clearly informed that treatment is likely 
to be lifelong and to require regular monitoring for 
optimal benefit.
Induction of male fertility
CHH manifests as a lack of gonadal development and 
infertility. Importantly, CHH is one of the rare treat-
able causes of male infertility. Spermatogenesis can be 
induced either by long-term pulsatile GnRH admin-
istration (pump)193 or more commonly by subcutan-
eous gonadotropin injections (2–3 times weekly).194–198 
These therapies induce both testicular testosterone 
production by Leydig cells and spermatogenesis in the 
seminiferous tubules.199–202 The majority of patients 
with CHH develop sperm in their ejaculate with long-
term therapy.149,193,196,197 Although these treatments 
seem to have similar fertility outcomes,199–202 compar-
ing their efficacy is difficult owing to the small numbers 
of patients studied, heterogeneity in terms of degrees of 
GnRH deficiency (testicular volume before treatment), 
prior treatment and a lack of randomized studies 
 performed to date.
A number of predictors of fertility outcome have 
emerged in CHH. First, cryptorchidism indicates a 
poor fertility prognosis.193,195 Men with CHH who have 
cryptor chidism often require extended courses of treat-
ment (18–24 months).203,204 Prepubertal testicular volume 
(<4 ml) and/or low serum levels of inhibin B are also neg-
ative determinants of fertility outcome.193–197 Clinicians 
should be aware that although ~75% of men will develop 
sperm, counts rarely reach the normal range with long-
term therapy. A 2014 meta-analysis identified a mean 
sperm count of 5.9 × 106/ml (range: 4.7–7.1 × 106/ml) 
for gonadotropin therapy and 4.3 × 106/ml (range: 
1.8–6.7 × 106/ml) for GnRH therapy.200 However, an 
important feature of patients with CHH is that low sperm 
concentrations do not preclude fertility.205
In clinical practice, when testicular volume is <4 ml, the 
classic treatment is either pulsatile GnRH (25 ng/kg every 
2 h, titrated for trough serum testosterone level) or com-
bined gonadotropin therapy (hCG: 1,000–1,500 IU  + FSH: 
75–150 IU 2–3 times weekly, based on available formu-
lations). In patients with some gonadal development 
(testicular volume >4 ml) and no history of cryptorchi-
dism, induction of spermatogenesis can be achieved 
with hCG mono therapy.194,206–208 If no sperm is present 
in the ejaculate after 3–6 months of treatment, FSH can 
be used to stimulate the seminiferous tubules.198 In the 
most severely affected men with CHH (testicular volume 
<4 ml), a sequential treatment has emerged in an attempt 
to maximize fertility potential.10,209,210 The unopposed FSH 
treatment before maturation by hCG (or alternatively, 
GnRH-induced LH) stimulates proliferation of imma-
ture Sertoli and germ cells. Outcomes of patients treated 
with this regimen demonstrate successful induction of tes-
ticular development and fertility in men with CHH who 
have prepubertal testes.10,210 To definitively determine the 
optimal approach to fertility treatment in men with CHH 
and severe GnRH deficiency (with or without cryptorchi-
dism), an international,  multicentre randomized trial is 
needed (Box 3).
Assessment of the fertility status of the female 
partner is crucial before induction of spermatogen-
esis and includes a detailed reproductive and/or men-
strual history and evaluation of the integrity of the 
uterine cavity and tubal permeability (by use of sono- 
hysterosalpingography or hysterosalpingography). 
Anovulation and ovarian reserve can be assessed via a 
combination of history of menstrual cycle abnormali-
ties, laboratory examination and pelvic ultrasonography. 
Couples should be counselled appropriately on the basis 
of the identified predictors of CHH fertility-inducing 
treatment,193–198,200 as well as the partner’s reproductive 
status and age in order to develop realistic expectations 
regarding treatment outcome.
For men with CHH who have severely impaired 
sperm counts (or quality), assisted reproductive technol-
ogy (ART) treatments such as in vitro fertilization can 
be used to improve fertility. More invasive procedures 
than ART include surgical testicular sperm extraction 
followed by in vitro intracytoplasmic sperm injection 
(ICSI). ICSI was initially used in men with CHH as a 
means to shorten the duration of treatment;211 however, 
outcomes are improved after maximal testicular volume 
is attained. Overall, fertilization is achieved in 50–60% 
of cases of ICSI, with pregnancy occurring in about a 
third of cycles.212–215 Although a study of sperm quality 
in men with CHH who received fertility-inducing treat-
ment revealed neither altered DNA integrity nor an 
increased risk of chromosomal abnormalities,216 the 
possibility of an increased risk of birth defects with ART 
remains controversial. Once pregnancy is achieved, men 
with CHH can be transitioned to testosterone replace-
ment therapy (injectable or transdermal preparations) 
for long-term treatment. Our consensus is that treat-
ment be continued through the first trimester of preg-
nancy, in order to maintain male fertility capability in 
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the event of miscarriage. Furthermore, although previous 
gonadotropin cycles seem to shorten the time to fertility 
in subsequent treatments,196 fertility in the future is not 
guaranteed. We, thus, recommend cryopreserving sperm 
once fertility has been attained.
Induction of female sexual characteristics
Puberty can be induced by oral or preferably transder-
mal estradiol administration in girls. The use of specific 
low-dose estradiol formulations (for example, 0.1 mg 
daily) are important.174 Transdermal estradiol adminis-
tration is started (from age 10 years at the earliest) at low 
doses (typically 0.05–0.07 μg/kg nocturnally), with the 
goal of mimicking estradiol levels during gonadarche. 
In older girls, when breast development is a high pri-
ority, the starting dose of transdermal estradiol can be 
0.08–0.12 μg/kg.217 The estradiol dose is slowly increased 
over 12–24 months, after which time cyclic gestagen is 
added (or after the first menstrual bleed) in order to max-
imize breast development. In adulthood, estradiol is typi-
cally given orally (at a dose of 1–2 mg) or transdermally 
(50 μg daily by patch or 1–2 pumps of 0.06% gel daily) 
as a maintenance dose with a cyclic progestin regimen 
(progesterone 200 mg for 14 days of the cycle, depending 
on formulation) to avoid endometrial hyperplasia. In the 
majority of women with CHH, estroprogestin therapy 
is effective in inducing harmonious development of the 
breasts and genitals, as well as an increased sense of femi-
ninity that contributes to a satisfactory emotional and 
sexual life. Estrogen treatment increases uterine size 
and combined estrogen and progestin therapy induces 
monthly withdrawal bleeding, but does not induce ovu-
lation. For fertility, gonadotropins or GnRH therapy are 
necessary and effective.
Table 4 | Approach to treatment of CHH
Target 
population
Goals Treatment Clinical monitoring Laboratory 
monitoring
Comments
Neonatal and childhood
Male 
individuals with 
cryptorchidism 
with or without 
micropenis
Testicular 
descent
Cryptorchidism: orchidopexy 
(patients aged <1 year)
Testicular volume Testosterone, LH, 
FSH, inhibin B and 
AMH levels
Baseline levels of 
testosterone, LH and FSH 
between days 14–90; for 
later timepoints, measure 
after GnRH agonist 
stimulation
No current indication for 
female individuals
Penis growth Micropenis: testosterone, DHT 
or gonadotropin therapy 
(patients aged 1–6 months)
Penile growth
Adolescent
Patients aged 
14–15 years 
(earlier in the 
presence of 
specific signs 
such as 
anosmia)
Virilization or 
estrogenization
Sexual function
Growth and bone 
health
Gonadal 
maturation and 
future fertility
Psychological 
wellbeing
Male patients: testosterone 
(oral, injectable or 
transdermal)
Gonadotropins?
Genital development
Growth and epiphyseal closure
Virilization
Sexual function
Wellbeing
Adherence
Reversibility
Morning serum 
testosterone levels 
(trough levels for 
injections), LH, 
FSH and inhibin B 
levels, haemocrit
Testosterone treatment will 
not induce testicular growth 
or fertility
Female patients:
estradiol (oral or transdermal) 
followed by estradiol +  
progesterone or progestin
Breast development
Growth and epiphyseal closure
Estrogenization
Feminized body
Menses
Sexual function
Bone health
Wellbeing
Adherence
Reversibility
No specific Estradiol must be increased 
slowly before the combination 
of estradiol + progesterone or 
progestin to maximize breast 
development and avoid 
areolar protrusion
Adulthood
All patients Sexual function
Fertility
Limiting 
comorbidities
Psychological 
wellbeing
Puberty 
induction
Male patients:
Testosterone (injectable  
or transdermal)
hCG ± FSH
FSH, FSH + hCG
GnRH pump
Pubertal development
Sexual function and libido
Bone health
Wellbeing
Adherence
Fertility
Reversibility
Tough serum 
testosterone levels, 
LH, FSH and 
inhibin B levels, 
haematocrit, 
PSA levels
Sex steroid replacement 
will not induce fertility
Female patients:
Estradiol (oral or transdermal)
Progesterone or progestin
FSH + hCG or GnRH pump
Pubertal development
Sexual function and libido
Bone health
Wellbeing
Adherence
Fertility
Reversibility
Serum levels of 
estradiol, LH, FSH, 
inhibin B and AMH
Sex steroid replacement 
will not induce fertility
Abbreviations: AMH, anti-Müllerian hormone; CHH, congenital hypogonadotropic hypogonadism; DHT, dihydrotestosterone; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing 
hormone; hCG, human chorionic gonadotropin; LH, luteinizing hormone; PSA, prostate-specific antigen.
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Induction of female fertility
Infertility in women with CHH is related to insufficient 
follicular maturation, which leads to chronic anovula-
tion.218 GnRH-induced pituitary gonadotropins induce 
absent or decreased physiological ovarian stimulation; 
however, no evidence of a decreased follicular reserve 
exists. This point must be emphasized as decreased circu-
lating AMH concentrations observed in female patients 
with CHH and severe GnRH deficiency could wrongly 
suggest an alteration in ovarian reserve and therefore 
a poor fertility prognosis.219 By contrast, women with 
CHH should be informed that their infertility is treat-
able and that their reproductive prognosis is quite good 
in the absence of a male factor of infertility.
Before considering ovulation induction, sono- 
hysterosalpingography or hysterosalpingography should 
be performed to evaluate the integrity of the uterine cavity 
and fallopian tubes. One must also ensure regular sexual 
intercourse takes place and rule-out an associated male 
factor in infertility by semen analysis.220 Couples should 
be advised on the optimal timing of sexual intercourse 
during the ovulation induction as this first-line therapy 
does not require in vitro fertilization.221 The goal of ovu-
lation induction therapy in female patients with CHH is 
to obtain a single ovulation and to avoid multiple preg-
nancies. Ovulation can be achieved either with pulsatile 
GnRH therapy222–224 or, alternatively, with FSH treatment 
followed by hCG or LH to trigger ovulation.225 One caveat 
is that most women with CHH do not secrete endogenous 
LH and, thus, require a complement of LH to stimulate 
local production of androgen substrates by theca cells, 
which facilitates sufficient secretion of estradiol by the 
dominant follicle.226–228 Physiologic estradiol secretion 
promotes optimal endometrial development and the 
cervical mucus production needed for sperm transit and 
embryo implantation.229 Typically, subcutaneous FSH 
doses of 75–150 IU per day are sufficient.223–225,229 The 
usual time required to obtain a dominant mature follicle 
(>18 mm) is ~12 days.223–225,229 The starting dose of FSH 
is often increased or decreased depending on the ovarian 
response, as assessed by repeated serum estradiol meas-
urements or by counting maturing follicles (using ultra-
sonography) performed approximately every 3–4 days. 
This regimen helps to minimize multiple pregnancies and 
the risk of ovarian hyperstimulation syndrome.230 After 
ovulation, progesterone production can be stimulated by 
repeated hCG injections or direct administration of pro-
gesterone during the postovulatory phase, until embryonic 
endogenous hCG secretion takes over.
Ovulation induction with a pulsatile GnRH pump can 
be effective even in the presence of GnRH resistance, 
such as in women with CHH who have mutations in 
GNRHR.231 GnRH can be administered at different pulse 
frequencies across the cycle, mimicking physiological 
ovarian stimulation.232 Alternatively, pulsatile GnRH at a 
constant frequency also induces maturation of ovarian fol-
licles and triggers an LH peak. The usual doses comprise 
3–10 μg per pulse, injected subcutaneously every 90 min. 
Monitoring ovulation induction with GnRH is useful, as 
the risk of multiple pregnancy and ovarian hyperstimula-
tion syndrome is much lower than that with gonadotropin 
therapy.233 Once ovulation is obtained, the corpus luteum 
is stimulated to produce progesterone, which is neces-
sary for embryo implantation. Short-term GnRH treat-
ment is necessary to induce progesterone release until the 
 endo genous secretion of hCG from the embryo begins.
Reducing long-term health effects of CHH
With appropriate and long-term treatment, many of the 
long-term effects of hypogonadism can be minimized. 
Adherence to treatment is key to supporting pubertal 
development, sexual function and psychological health.234 
Patients with psychosexual problems, low self-esteem and 
distorted body image might require psychological coun-
selling and often benefit from peer–peer support.98,192 
Bone-health concerns in patients with CHH are well-
recognized.235 Lack of sex steroids is the presumed cause 
Box 3 | Challenges for management of CHH and goals
Detection and diagnosis of CHH
 ■ Discover novel biomarkers for CHH diagnosis and 
assess the utility of refining the phenotype to enhance 
genetic testing
Best treatment and timing of initiating treatment
 ■ Long-term studies evaluating: neonatal gonadotropin 
treatment to optimize fertility; gonadotropin treatment 
during adolescence versus adulthood for fertility 
optimization; and role of prior androgen treatments 
on fertility outcomes
Adherence to treatment and transition to adult services
 ■ Interventions to promote adherence and structured 
transitional care from paediatric to adult services
Psychological distress and psychosexual effect
 ■ Targeted psychosocial interventions and enhanced 
peer-to-peer support
Specialized care for fertility induction
 ■ International, multicentre trials to identify optimal 
approach to treatment
Genetic counselling (monogenic versus oligogenic forms 
of CHH)
 ■ Personalized counselling of patients using results 
obtained by next-generation sequencing technologies
Abbreviation: CHH, congenital hypogonadotropic hypogonadism.
Box 4 | Goals for testosterone replacement therapy*
Promote
 ■ Virilization (for example, axillary, body and facial hair)
 ■ Development of muscle mass and strength
 ■ Pubertal growth spurt
 ■ Skeletal maturation and bone mass
 ■ Deepening of voice
 ■ Growth of penis
 ■ Libido and sexual function
 ■ Self-confidence and wellbeing
Monitor and minimize
 ■ Acne
 ■ Gynaecomastia
 ■ Aggressiveness
 ■ Polycythaemia
*In male patients with congenital hypogonadotropic hypogonadism.
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of osteoporosis in patients with CHH236–238 and although 
sex steroid treatment typically improves bone density, it 
does not fully reverse the pheno type. Notably, mutations 
in FGF8, FGFR1 or SEMA3A might not only cause GnRH 
deficiency but also directly affect bone.153,239 We recom-
mend a baseline bone density measurement in all patients 
with CHH at final height and after 2 years of treatment. To 
date, insufficient evidence exists to use the WHO–FRAX 
risk calculator240 in this population of patients. Long-term 
effects of hypo gonadism also include an increased risk of 
developing metabolic problems. Several meta-analyses 
have demonstrated an association between low testos-
terone levels and the metabolic syndrome.241–244 In male 
individuals, low testosterone levels are also strongly associ-
ated with an increased risk of developing type 2 diabetes 
mellitus.245 However, few studies have examined metabolic 
risk specifically in patients with CHH. Interestingly, even 
short-term hypogonadism (such as that resulting from dis-
continuation of sex steroids for 2 weeks) induces increased 
fasting insulin concentrations in young men with CHH,246 
which suggests that adherence to treatment is also impor-
tant for promoting metabolic health. Accordingly, thera-
peutic education is important for promoting adherence in 
the ongoing management of CHH.
Transitional care for CHH
Transition of young adults from paediatric care to adult 
care is a well-recognized challenge for patients with 
chronic endocrine conditions247,248 including CHH.175 
For patients with CHH, discontinuation of care and 
resulting gaps in treatment can have considerable health 
consequences. Several types of model for transition 
exist from a simple transfer of care to more structured 
programmes.249 Consensus among paediatric and adult 
endocrinologists in the European consortium study-
ing GnRH biology (COST Action BM1105, http:// 
www.gnrhnetwork.eu/) is that a structured transition is 
preferable and the process should include an evaluation of 
patient readiness, communication between providers and 
follow-up to ensure that the initial consultation has been 
completed. The timing of transition not only depends on 
structural aspects of a given health-care system but also 
on the individual patient’s psychological and emotional 
development and capacity for autonomy and self-care.
Conclusions
CHH is a condition that is clinically and genetically 
hetero geneous. It is often challenging to diagnose, par-
ticularly during adolescence. In male individuals, crypt-
orchidism with or without micropenis might suggest 
neonatal CHH; however, similarly useful signs are lacking 
for female individuals. During adolescence, the diagnosis 
of CHH is difficult to discern from constitutional delay of 
growth and puberty. The presence of anosmia and/or 
olfactory bulb hypoplasia and/or aplasia (visualized by 
MRI) points to Kallmann syndrome, yet measurement 
of levels of serum gonadotropins, sex steroids, AMH and 
inhibin B are not always fully informative in confirming 
the diagnosis. At this stage, pubertal induction is com-
menced and a clinical and/or biochemical reassessment 
is conducted following therapeutic pause at final height, 
thus enabling a definitive diagnosis of CHH. Effective 
treatment is available not only for inducing virilization 
or estrogenization, but also for successful development of 
fertility. Advances in our understanding of the molecular 
basis of CHH have helped explain the genetic cause in 
50% of cases and uncovered a complex model of gen etics 
(oligo genicity) that might apply to a large proportion of 
patients. Furthermore, cases of reversal in adulthood 
point to gene–environment interactions.6,7 To advance 
the field, identification of novel biomarkers to aid early 
diagnosis of CHH, assembly of a large CHH population 
to study the complex molecular basis of the disease, and 
development of targeted treatments to optimize fertility 
outcomes are important. The COST network was created 
to address these issues as well as to promote translational 
research into human reproduction and improve the 
manage ment of CHH.
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